Investors & Media

Sep 17, 2019 /

Sep 17, 2019 / Sep 17, 2019 /

Recent News

9/17/19

BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common Shares
LAVAL, Quebec --(BUSINESS WIRE)--Sep. 17, 2019-- BELLUS Health Inc. (“ BELLUS Health” or the “Company”) (Nasdaq: BLU; TSX: BLU), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today...
Read More
9/9/19

BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United States
LAVAL, Quebec --(BUSINESS WIRE)--Sep. 9, 2019-- BELLUS Health Inc. (“ BELLUS Health” or the “Company”) (Nasdaq: BLU; TSX: BLU), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More
9/5/19

BELLUS Health Announces Pricing of US$70 Million Public Offering in Canada and the United States
- Common Shares to Begin Trading on Nasdaq - LAVAL, Quebec --(BUSINESS WIRE)--Sep. 5, 2019-- In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“ BELLUS Health” or the “Company”) (TSX: BLU) today...
Read More